| Literature DB >> 29244191 |
Georg Sager1,2, Natalia Smaglyukova1, Ole-Martin Fuskevaag1,2.
Abstract
The present study was conducted to characterise the transporter(s) responsible for the uptake of <span class="Chemical">cyclic nucleotides to <span class="Species">human erythrocytes. Western blotting showed that hRBC expressed OAT2 (SLC22A7), but detection of OAT1 (SLC22A6), or OAT3 (SLC22A8) was not possible. Intact hRBC were employed to clarify the simultaneous cyclic nucleotide egression and uptake. Both these opposing processes were studied. The Km -values for high affinity efflux was 3.5 ± 0.1 and 39.4 ± 5.7 μM for cGMP and cAMP, respectively. The respective values for low affinity efflux were 212 ± 11 and 339 ± 42 μM. The uptake was characterised with apparently low affinity and similar Km -values for cGMP (2.2 mM) and cAMP (0.89 mM). Using an iterative approach in order to balance uptake with efflux, the predicted real Km -values for uptake were 100-200 μM for cGMP and 50-150 μM for cAMP. The established OAT2-substrate indomethacin showed a competitive interaction with cyclic nucleotide uptake. Creatinine, also an OAT2 substrate, showed saturable uptake with a Km of 854 ± 98 μM. Unexpectedly, co-incubation with cyclic nucleotides showed an uncompetitive inhibition. The observed Km -values were 399 ± 44 and 259 ± 30 μM for creatinine, in the presence of cGMP and cAMP, respectively. Finally, the OAT1-substrate para-aminohippurate (PAH) showed some uptake (Km -value of 2.0 ± 0.4 mM) but did not interact with cyclic nucleotide or indomethacin transport.Entities:
Keywords: OAT2; SLC22A7; cAMP; cGMP; human erythrocytes
Mesh:
Substances:
Year: 2018 PMID: 29244191 PMCID: PMC5947735 DOI: 10.1002/jcp.26409
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384
Figure 1Western blotting of OAT1, OAT2, and OAT3 expression in hRBC membranes. Panel A: Positive control, OAT2 in Jurkat whole cell lysate and OAT‐2 expression in hRBC membranes from three female donor (donor 1–3; applied 50 µg of total protein per lane), and three male donor (donor 4–6; applied 50 µg of total protein per lane). Panel B: Positive control, OAT1 in HEK 293T cell over‐expression lysate and absence of OAT1 expression in hRBC membranes from three female donor (donor 1–3; applied 50 µg of total protein per lane), and three male donor (donor 4–6: applied 50 µg of total protein per lane). Panel C: Positive control, OAT3 in Jurkat whole cell lysate and absence of OAT 3 expression in hRBC membranes from three female donor (donor 1–3; applied 50 µg of total protein per lane), and three male donor (donor 4–6; applied 50 µg of total protein per lane). Na/K‐ATPase α1 was used as an internal control
The cells were loaded with cyclic nucleotides and the efflux initiated at 37 °C and terminated after 120 min
| High affinity | Low affinity | |||
|---|---|---|---|---|
| Km (µM) | Vmaxa | Km (µM) | Vmaxa | |
| cGMP ( | 3.5 ± 0.1 | 0.146 ± 0.044 | 212 ± 11 | 0.541 ± 0.134 |
| cAMP ( | 39.4 ± 5.7 | 0.222 ± 0.074 | 339 ± 42 | 0.947 ± 0.364 |
The levels of cGMP and cAMP were determined with a HPLC assay (described in methods). The results are presented as mean value ± SD and the number of time‐independent experiments in parenthesis.
apmol per 109 cells per min.
Figure 2Panel A shows uptake of cyclic nucleotides during an incubation period of 120 min. Washed hRBC were incubated with 10 μM cyclic nucleotide at 37 °C. The intracellular concentrations were determined with LC‐MS/MS as described in methods. Three time‐independent experiments were performed with cGMP (● − ●) and cAMP (▴‐▴). Panel B shows a concentration‐dependent uptake of cyclic nucleotides from the buffered medium (160–5,000 μM) after 60 min at 37 °C, presented in a Lineweaver–Burk plot. Cyclic nucleotide concentrations were determined with HPLC as described in methods. Uptake of cGMP (n = 4) (● − ●) and cAMP (n = 5) (▴‐ ▴)
Observed Km and Vmax for the uptake of cGMP and cAMP after 60 min at 37 °C
| cGMP ( | cAMP ( | |
|---|---|---|
| Km (mM) | 2.2 ± 0.5 | 0.89 ± 0.12 |
| Vmax (pmol/min/109 cells) | 4.4 ± 0.5 | 3.7 ± 0.8 |
Cyclic nucleotide concentrations were determined with HPLC assay. The results are presented as mean value ± SD and the number of time‐independent experiments in parenthesis.
Figure 3Washed hRBC were incubated with 500 μM creatinine at 37 °C for periods up to 120 min. Intracellular concentrations were determined with LC‐MS/MS. The results from three time‐independent experiments (each in duplicate) are presented as mean ± SD, n = 3
Creatinine uptake in absence and the presence of cyclic nucleotides
| Km (µM) | Vmaxa | |
|---|---|---|
| Creatinine | 854 ± 98 ( | 1.7 ± 0.15 ( |
| Creatinine + cGMP | 399 ± 44 ( | 1.0 ± 0.14 ( |
| Creatinine + cAMP | 259 ± 30 ( | 0.8 ± 0.03 ( |
Nine creatinine concentrations (20–5000 μM) were incubated for 60 min at 37 °C in the absence and presence of 500 μM cGMP or 500 μM cAMP. Intracellular creatinine concentrations were obtained with LC‐MS/MS as described in methods. The results are presented as mean value ± SD and the number of time‐independent experiments in parenthesis.
aμmol/109 cells/min.
The transport of indomethacin, a mixture of [3H]‐indomethacin and unlabelled indomethacin (5–500 μM), was determined at 37 °C after 60 min incubation in the absence or in presence of cGMP (500 μM) or cAMP (500 μM) or PAH (500 μM)
| Competitor | Km (mM) | Vmaxb |
|---|---|---|
| None ( | 0.475 ± 0.08 | 2.6 ± 0.5 |
| cGMP ( | 2.3 ± 0.4a | 2.5 ± 0.4 |
| cAMP ( | 2.4 ± 0.2a | 2.6 ± 0.5 |
| PAH ( | 0.502 ± 0.1a | 2.1 ± 0.4 |
The resulting Km–values without inhibitor and apparent Km–values with inhibitors are given as mean value ± SD and number of time‐independent experiments.
aApparent Km for Indomethacin in presence of potential inhibitors.
bIndomethacin transport nmol/109 cells/min.